LXXGF - LXXGF STOCK NEWS

LexaGene Holdings announces participation in three prominent veterinary conferences in September 2021 to showcase its MiQLab System. Events include the WVC 93rd Annual Conference in Las Vegas from September 7-9, the International Veterinary Emergency and Critical Care Conference in Nashville from September 12-14, and the Southwest Veterinary Symposium in San Antonio from September 23-26. Dr. Jack Regan, CEO, emphasizes the potential market impact of in-clinic PCR diagnostics, aiming to enhance brand awareness and reach buyers.

LexaGene Holdings (OTCQB:LXXGF) will present at the SNN Network Summer Virtual Event 2021 on August 19, 2021, at 10:30 AM EST. Dr. Jack Regan, CEO and Founder, will lead the presentation. LexaGene, a molecular diagnostics company, has seen significant growth with its MiQLab™ system, enhancing veterinary diagnostics and biopharmaceutical manufacturing. The event offers 1on1 meetings with Dr. Regan and access to recorded presentations. For further details, visit LexaGene's website.

LexaGene Holdings, Inc. (OTCQB: LXXGF) announced its MiQLab™ System as the first point-of-need PCR system using both probe-based and SYBR Green chemistry. This flexibility addresses supply chain issues caused by COVID-19, enabling quicker reagent availability. Dr. Nathan Walsh highlighted that SYBR Green primers have notably shorter lead times. The MiQLab successfully detected Escherichia coli in tests. Dr. Jack Regan noted a potential 20% reduction in testing costs by using SYBR Green, underscoring the system's cost-effectiveness.

LexaGene Holdings announced the successful detection of mycoplasmas using its MiQLab System, which identified 100% of tested samples in under two hours, with no false positives. Mycoplasmas contaminate 15-80% of cell cultures globally, causing significant losses for biopharmaceutical manufacturers. The MiQLab can potentially reduce detection time by up to 300 times compared to traditional methods, which take around 28 days. This rapid detection is crucial for maintaining product safety and quality in bioprocessing, offering a competitive edge for the company in the diagnostics market.

LexaGene Holdings, a molecular diagnostics company, has engaged LaVoieHealthScience as its investor and public relations agency. This partnership aims to enhance visibility within the investment community, particularly as LexaGene prepares for a potential up-listing on the Nasdaq. LaVoieHealthScience specializes in life sciences communications, boasting extensive experience in healthcare. The collaboration includes a monthly fee of $18,000 for their services, ensuring a focused approach to corporate development and strategic communications.

LexaGene Holdings has announced that Meridian Veterinary Capital has purchased a MiQLab System for emergency and specialty veterinary hospitals. The MiQLab is designed for rapid pathogen detection, allowing veterinarians to diagnose and treat sick pets more efficiently. CEO Dr. Jack Regan expressed optimism about the growing traction in the veterinary market and the increasing confidence veterinarians gain from using the MiQLab. This system can detect up to 27 pathogens and is expected to enhance the quality of care provided to pets.

LexaGene Holdings has announced the presentation of its MiQLab™ System at the Biothreat and Pathogen Detection Conference. This innovative system is capable of rapidly detecting the plague pathogen, classified as a Category A Bioterrorism agent. Dr. Jack Regan highlighted the importance of quick diagnosis in biothreat containment, stating that it can significantly reduce response times for new pathogen detection. Recent tests have shown high sensitivity and specificity, with nearly 100% coverage of plague genomes, making MiQLab a crucial tool for public health safety.

LexaGene Holdings has announced the sale of another MiQLab™ System to Alpine Veterinary Hospital in California, indicating strong market demand in veterinary diagnostics. CEO Dr. Jack Regan will present at three upcoming conferences, focusing on advancements in microfluidics and pathogen detection. The company aims to enhance its presence in the veterinary health sector, generating multiple sales leads from recent events. LexaGene continues to develop its innovative diagnostic solutions, with an emphasis on antimicrobial stewardship and rapid testing capabilities.

LexaGene has demonstrated its MiQLab™ System can detect C. acnes 100% of the time in just 2 hours, significantly faster than traditional methods, which can take up to 3 days under optimal conditions and 14 days from bioreactor samples. This rapid detection could lead to substantial cost savings for biopharmaceutical manufacturers dealing with contamination. The increasing demand for vaccines and therapeutics underlines the need for efficient testing systems like MiQLab to maintain quality and minimize losses caused by microbial contamination during the manufacturing process.